In several brain diseases, including multiple sclerosis and spinal muscular atrophy, effective disease-modifying treatments can normalize NfL levels, and reduction in NfL levels is associated with the clinical effectiveness of the treatment.150,151. This evidence concerns the gene NEFL and spinal muscular atrophy.